Latest Epidermal growth factor receptor Stories
Peptides offer new approaches to interfere with EGFR and VEGFR pathways.
CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva(Â®) (erlotinib) in patients with non-small cell lung cancer (NSCLC).
One of the difficulties of fighting cancer is that drugs often hit other non-cancerous cells, causing patients to get sick.
The master gene called SRC-3 (steroid receptor coactivator 3) not only enhances estrogen-dependent growth of cancer cells by activating and encouraging the transcription of a genetic message into a protein, it also sends a signal to the cell membrane to promote cell motility or movement â€“ a key element of cancer spread or metastasis.
A new assay capable of examining hundreds of proteins at once and enabling new experiments that could dramatically change our understanding of cancer and other diseases has been invented by a team of University of Chicago scientists.
Researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine and Moores UCSD Cancer Center have shown one way in which gliomas, a deadly type of brain tumor, can evade drugs aimed at blocking a key cell signaling protein, epidermal growth factor receptor (EGFR),that is crucial for tumor growth.
Collaboration utilizes antibodies selectively targeting cancer cells combined with nuclear delivery technology developed at University of Toronto MISSISSAUGA, ON, Jan. 11 /PRNewswire-FirstCall/ - YM BioSciences Inc.
The interaction of enzymes â€“ especially the tyrosine kinases called Src and inducible nitric oxide synthase â€“ plays an important role in the growth of non-small cell lung cancers, the most common form of this deadly disease in the United States, said researchers from Baylor College of Medicine in a report in the Journal of Biological Chemistry.
The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.
- Therapure Biopharma to perform fill/finish of nimotuzumab - MISSISSAUGA, ON, Dec. 17 /PRNewswire-FirstCall/ - David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc.
- Growing in low tufty patches.